Sign In
Buy MRNA
$47.44
-4.15 (-8.04%)
At Close: Jun 05, 2026
Moderna (MRNA) Gears Up for Q4 Earnings: Will It Top Estimates?
12:05pm, Monday, 19'th Feb 2024
Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.
Nvidia, Walmart, Moderna, and More Stocks to Watch
02:00pm, Sunday, 18'th Feb 2024
The market is closed for Presidents Day on Monday. Then, Nvidia earnings, FOMC minutes, February Purchasing Managers' Indexes, and more.
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
06:46am, Thursday, 15'th Feb 2024
Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.
Here's Why Moderna (MRNA) Gained But Lagged the Market Today
06:51pm, Wednesday, 14'th Feb 2024
The latest trading day saw Moderna (MRNA) settling at $85.95, representing a +0.68% change from its previous close.
ChatGPT Stock Predictions: 3 Companies the AI Bot Thinks Have 10X Potential
06:00am, Wednesday, 14'th Feb 2024
In a time when AI is a friend and a guide through complex financial markets, AI-driven insights provide delight and optimism. Let us begin a deep dive into how ChatGPT, a sophisticated AI model, can g
Short sellers boosted by ‘Hedge Fund Nirvana' that sees most heavily-shorted companies suffer
07:47am, Monday, 12'th Feb 2024
Hedge funds with long/short strategies have benefited in 2024 from a macroeconomic environment that has hit the most heavily shorted stocks particularly hard compared to their less shorted rivals, a n
3 Doomed Biotech Stocks to Dump Before They Dive: February 2024
05:00pm, Sunday, 11'th Feb 2024
The unpredictable nature of the biotech industry, which frequently flirts with failure, underscores the inherent risks and rewards associated with doomed biotech stocks. The journey from drug discover
Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut
02:34pm, Friday, 09'th Feb 2024
Shares of Metagenomi Technologies , a genetic medicines company backed by Bayer Healthcare and Moderna , slumped 32% in their Nasdaq debut on Friday.
Moderna-backed Metagenomi cuts US IPO valuation target to $563 mln
11:07pm, Thursday, 08'th Feb 2024
Genetic medicines company Metagenomi Technologies MGX.O said on Thursday it is aiming for a valuation of $563 million in its U.S. initial public offering (IPO), a number that is at the low end of its
Moderna (MRNA) Stock Slides as Market Rises: Facts to Know Before You Trade
06:50pm, Wednesday, 07'th Feb 2024
In the most recent trading session, Moderna (MRNA) closed at $99.30, indicating a -0.73% shift from the previous trading day.
Moderna-backed Metagenomi targets up to $638 mln valuation for US IPO
06:24am, Monday, 05'th Feb 2024
Metagenomi Technologies, a genetic medicines company backed by Moderna , said on Monday it was targeting a valuation of up to $638 million for its initial public offering in New York.
Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
07:00am, Thursday, 01'st Feb 2024
CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to repo
1 Growth Stock Down 79% That's a Screaming Buy Right Now, According to Several Wall Street Analysts
05:50am, Friday, 26'th Jan 2024
Moderna's shares have plunged with declining demand for its COVID-19 vaccine. Several analysts have renewed optimism about the biotech stock as it expands beyond COVID.
Can Moderna's (MRNA) Launches Reduce COVID Sales Dependency?
02:41pm, Thursday, 25'th Jan 2024
With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next five years.
3 S&P 500 Stocks With 127% to 170% Upside in 2024, According to Select Wall Street Analysts
05:21am, Thursday, 25'th Jan 2024
The broad-based S&P 500 has been Wall Street's top "health" barometer for decades. High-water price targets from a trio of Wall Street analysts imply triple-digit gains to come for three S&P 500 compo
